What we do

Omixon is a global biotechnology company that commercializes disruptive innovations specializing in targeted applications for Next Generation Sequencing (NGS). The Omixon Holotype HLA™ product combines a targeted HLA Assay and the Omixon HLA Twin™ software to deliver the most accurate high-resolution HLA genotyping available. Omixon maintains an active grant-funded research program and assists scientists and clinicians to analyze the most challenging genomic regions including HLA, KIR and ABO.


Omixon Blog

Webinar – Rare & Null Allele Detection with HLA Twin™

Are you interested in Orthogonal Bioinformatic Validation?    Watch this latest webinar presentation on HLA Twin™ – Rare & Null Allele Detection   Date: Thursday, 11th December, 2014 Time: 12:00–13:00pm EST (18:00–19:00pm CET) A live Q&A session will follow the presentation, offering you the …more

By kriszta.katona 0 comments

Patient Stratification in Clinical Trials

When carrying out clinical trials, one of the most important logistical and statistical challenges is ensuring that your data accurately reflects the population you are setting out to study. None of us has the resources to test a drug on …more

By kriszta.katona 0 comments